NVDA

175.84

+1.77%↑

AAPL

251.14

+1.34%↑

MSFT

383.14

+0.45%↑

TSM

338.8

+2.99%↑

AVGO.US

322.68

+4.05%↑

NVDA

175.84

+1.77%↑

AAPL

251.14

+1.34%↑

MSFT

383.14

+0.45%↑

TSM

338.8

+2.99%↑

AVGO.US

322.68

+4.05%↑

NVDA

175.84

+1.77%↑

AAPL

251.14

+1.34%↑

MSFT

383.14

+0.45%↑

TSM

338.8

+2.99%↑

AVGO.US

322.68

+4.05%↑

NVDA

175.84

+1.77%↑

AAPL

251.14

+1.34%↑

MSFT

383.14

+0.45%↑

TSM

338.8

+2.99%↑

AVGO.US

322.68

+4.05%↑

NVDA

175.84

+1.77%↑

AAPL

251.14

+1.34%↑

MSFT

383.14

+0.45%↑

TSM

338.8

+2.99%↑

AVGO.US

322.68

+4.05%↑

Search

Rapid7 Inc

Uždarymo kaina

SektoriusTechnologijų sektorius

6.31 0.8

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

6.09

Max

6.44

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-6.7M

3.1M

Pardavimai

-572K

217M

P/E

Sektoriaus vid.

17.5

77.27

Pelnas, tenkantis vienai akcijai

0.44

Pelno marža

1.439

Darbuotojai

2,613

EBITDA

-3.6M

19M

Rekomendacijos

By TipRanks

Rekomendacijos

Neutralu

12 mėnesių prognozė

+56.74% upside

Dividendai

By Dow Jones

Kitas uždarbis

2026-05-11

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-289M

415M

Ankstesnė atidarymo kaina

5.51

Ankstesnė uždarymo kaina

6.31

Naujienos nuotaikos

By Acuity

61%

39%

148 / 376 reitingas Technology

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Bearish Evidence

Rapid7 Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-03-23 23:47; UTC

Įsigijimai, susijungimai, perėmimai

Gilead Sciences to Buy Ouro Medicines, Collaborate With Galapagos on Purchased Assets -- Update

2026-03-23 22:55; UTC

Įsigijimai, susijungimai, perėmimai

Gilead Sciences to Buy Ouro Medicines for Up to $2.18 Billion

2026-03-23 21:51; UTC

Įsigijimai, susijungimai, perėmimai

Italy's Postal Service Makes $12.50 Billion Bid for Telecom Italia -- 3rd Update

2026-03-23 23:59; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-03-23 23:59; UTC

Rinkos pokalbiai

Woodside, Santos Earnings Power Up on Surging LNG Prices -- Market Talk

2026-03-23 23:50; UTC

Rinkos pokalbiai

Nikkei May Rise on Hopes for U.S. Talks With Iran -- Market Talk

2026-03-23 23:37; UTC

Rinkos pokalbiai

Gold Rises, Boosted by Fall in Dollar, U.S. Treasury Yields -- Market Talk

2026-03-23 22:42; UTC

Rinkos pokalbiai
Svarbiausios naujienos

Global Equities Roundup: Market Talk

2026-03-23 22:42; UTC

Rinkos pokalbiai
Svarbiausios naujienos

Bell Potter Names Miners Less Exposed to Fuel Price, Supply Risks -- Market Talk

2026-03-23 22:40; UTC

Įsigijimai, susijungimai, perėmimai

Gilead Sciences to Buy Ouro Medicines for Up to $2.18B

2026-03-23 22:23; UTC

Rinkos pokalbiai

Apollo Debt Solutions Shrugs Off Private-Credit Fears -- Market Talk

2026-03-23 22:22; UTC

Įsigijimai, susijungimai, perėmimai

Gilead Sciences: OM336 Is for Treatment of Autoantibodies Driven Immune-Mediated Disease

2026-03-23 22:21; UTC

Įsigijimai, susijungimai, perėmimai

Gilead Sciences: Company Would Pay Galapagos Royalties of 20%-23% of Net OM336 Sales

2026-03-23 22:21; UTC

Įsigijimai, susijungimai, perėmimai

Gilead Sciences: Company Would Retain Sole Worldwide Commercialization Rights of OM336 Outside of Greater China

2026-03-23 22:20; UTC

Įsigijimai, susijungimai, perėmimai

Gilead Sciences: Company, Galapagos Would Collaborate on Development of OM336 >GILD

2026-03-23 22:20; UTC

Įsigijimai, susijungimai, perėmimai

Gilead Sciences: Galapagos Would Absorb Substantially All of Ouro's Operating Assets, Retain Its Employees >GILD

2026-03-23 22:19; UTC

Įsigijimai, susijungimai, perėmimai

Gilead Sciences: Galapagos Would Pay 50% of Upfront Consideration and 50% of Any Contingent Milestone Payments Payable to Ouro Shareholders

2026-03-23 22:19; UTC

Įsigijimai, susijungimai, perėmimai

Gilead Sciences: Currently in Advanced Discussions With Galapagos With Respect to Potential Research-and-Development Collaboration on Acquired Ouro Assets

2026-03-23 22:18; UTC

Įsigijimai, susijungimai, perėmimai

Gilead Sciences to Buy Ouro Medicines for About $1.68B Upfront, Up to $500M in Contingent Milestone Payments >GILD

2026-03-23 22:15; UTC

Įsigijimai, susijungimai, perėmimai

Gilead Sciences To Acquire Ouro Medicines To Advance First In Class T Cell Engager Program For Autoimmune Diseases >GILD

2026-03-23 22:08; UTC

Rinkos pokalbiai

Ebos Needs to Reset Its Gearing Targets -- Market Talk

2026-03-23 21:42; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-03-23 21:42; UTC

Rinkos pokalbiai

RBNZ's Breman Strikes Reassuring Tone On Rates -- Market Talk

2026-03-23 21:32; UTC

Uždarbis

WuXi XDC Cayman: Results Aided by Strong Growth in Contract Research, Development and Manufacturing Organisation Business>2268.HK

2026-03-23 21:32; UTC

Uždarbis

WuXi XDC Cayman 2025 Net CNY1.56B Vs. Net CNY917.16M >2268.HK

2026-03-23 21:32; UTC

Uždarbis

WuXi XDC Cayman 2025 Rev CNY5.94B Vs. CNY4.05B >2268.HK

2026-03-23 21:10; UTC

Svarbiausios naujienos

Oil Is Back Under $100. Trump Says Iran Has Agreed to No Nuclear Weapons. -- Barrons.com

2026-03-23 20:50; UTC

Rinkos pokalbiai

Tech, Media & Telecom Roundup: Market Talk

2026-03-23 20:50; UTC

Rinkos pokalbiai

Health Care Roundup: Market Talk

2026-03-23 20:50; UTC

Rinkos pokalbiai
Uždarbis
Svarbiausios naujienos

Basic Materials Roundup: Market Talk

Akcijų palyginimas

Kainos pokytis

Rapid7 Inc Prognozė

Kainos tikslas

By TipRanks

56.74% į viršų

12 mėnesių prognozė

Vidutinis 9.89 USD  56.74%

Aukščiausias 12 USD

Žemiausias 6.5 USD

Remiantis 21 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Rapid7 Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Neutralu

21 ratings

1

Pirkti

18

Laikyti

2

Parduoti

Techninis įvertinimas

By Trading Central

28.34 / 28.82Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Bearish Evidence

Vidutinės trukmės periodas

Bearish Evidence

Ilgalaikis periodas

Bullish Evidence

Rinkos nuotaikos

By Acuity

148 / 376 reitingas Technologijų sektorius

Naujienos nuotaikos

Meškų rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Rapid7 Inc

Rapid7, Inc. provides cybersecurity solutions under the Rapid7, Nexpose, and Metasploit brand names. The company offers endpoint to cloud data collection and sharing applications, such as Rapid7 Insight Agent, a software-based agent that is used on assets across on-premises and cloud environments to centralize and monitor data on company's platform; Rapid7 Insight Network Sensor that analyzes raw end-to-end network traffic to increase visibility into user activity, pinpoint real threats, and investigations; Rapid7 Cloud Event Data Harvesting that offers visibility into changes made to cloud resources; and third-party integrations and ecosystem, as well as orchestration and automation solutions. It also offers various platforms, including Rapid7 managed threat complete consisting of managed detection response that delivers end-to-end threat detection and response, as well as offloads day-to-day vulnerability management operations. In addition, it provides Rapid7 threat complete consisting of InsightIDR, a security information and event management, and extended detection and response solution; and InsightVM, a vulnerability management solution that provides visibility across on-premise and remote endpoints for security teams to evaluate the business risks, and configurations, and share with their IT counterparts for remediation. Further, the company offers Rapid7 cloud risk complete, which includes InsightCloudSec, a cloud risk and compliance management solution; and InsightAppSec, a dynamic application security testing tool. It also provides professional services. It serves a range of industries, including business services, pharmaceuticals, technology, energy, financial services, healthcare and life sciences, manufacturing, media and entertainment, retail, education, real estate, travel and transportation, government, online services, telecommunications, and professional services. The company was incorporated in 2000 and is headquartered in Boston, Massachusetts.
help-icon Live chat